Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor

BACKGROUND: Mutations in POLE /POLD1 proofreading domain can cause deficiencies in DNA repair, conferring ultramutated cancer phenotypes. Preliminary clinical studies have revealed an association between POLE/POLD1 mutations and beneficial clinical outcomes to immune checkpoint inhibitor (ICI) thera...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Junjun, Ouyang, Wei, Zhao, Wugan, Shao, Lin, Li, Bing, Liu, Bihao, Wang, Dejuan, Han-Zhang, Han, Zhang, Zhou, Shao, Liang, Li, Wencai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867935/
https://www.ncbi.nlm.nih.gov/pubmed/33569431
http://dx.doi.org/10.21037/atm-20-7553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867935/
https://www.ncbi.nlm.nih.gov/pubmed/33569431
http://dx.doi.org/10.21037/atm-20-7553

Ejemplares similares